Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta-Analysis
- PMID: 38898622
- DOI: 10.1111/hel.13103
Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta-Analysis
Abstract
Introduction: Due to irregular antibiotic use, the rate of antibiotic resistance to Helicobacter pylori (H. pylori) is increasing and varies from region to region. Therefore, for the purpose of further clarifying the changes in antibiotic resistance rates nowadays, we conducted a systematic review and meta-analysis to update and assess the 10-year trend of primary H. pylori antibiotic resistance rate to the commonly prescribed antibiotics worldwide.
Materials and methods: According to the PRISMA statement, we systematically searched electronic databases for studies that assessed rates of H. pylori resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, or tetracycline published from 2013 to 2023. AHRQ was adopted to estimate methodological quality and publication bias in the included studies, and statistical analysis was performed using Stata 17.0.
Results: We identified 163 studies, comprising 47,002 isolates from 36 countries. The meta-analysis showed that the primary antibiotic resistance rate of H. pylori varied widely among antibiotics. Subgroup analysis showed higher rates of antibiotic resistance in the adult population than in children, and a general trend of increased resistance was observed from 2013 to 2023. There was considerable heterogeneity (I2 > 75%) among all analyses, which may be due to high variability in resistance rates across the global regions.
Conclusions: Resistance of H. pylori to antibiotics has reached alarming levels worldwide, which has a great effect on the efficacy of treatment. Local surveillance networks are required to select appropriate eradication regimens for each region.
Keywords: Helicobacter pylori; meta‐analysis; primary antibiotic resistance; systematic review.
© 2024 John Wiley & Sons Ltd.
Similar articles
-
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.Gastroenterology. 2018 Nov;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007. Epub 2018 Jul 7. Gastroenterology. 2018. PMID: 29990487 Free PMC article.
-
Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2016 Jun 28;2016(6):CD009034. doi: 10.1002/14651858.CD009034.pub2. Cochrane Database Syst Rev. 2016. PMID: 27351542 Free PMC article.
-
Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2017 Oct;2(10):707-715. doi: 10.1016/S2468-1253(17)30219-4. Epub 2017 Aug 7. Lancet Gastroenterol Hepatol. 2017. PMID: 28781119
-
Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review.Helicobacter. 2024 Jan-Feb;29(1):e13057. doi: 10.1111/hel.13057. Helicobacter. 2024. PMID: 38415810
-
Helicobacter pylori and gastric or duodenal ulcer.Prescrire Int. 2016 Jan;25(167):18-23. Prescrire Int. 2016. PMID: 26942258
Cited by
-
Smartphone-based colorimetric detection of urease activity in dental plaque for point-of-care screening of Helicobacter pylori infection.Mikrochim Acta. 2025 Sep 13;192(10):666. doi: 10.1007/s00604-025-07496-0. Mikrochim Acta. 2025. PMID: 40944762
-
Epidemiological characteristics of Helicobacter pylori infection and antibiotic resistance in urban areas of Guangdong Province, China: a multi-center, cross-sectional surveillance.Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1305-1312. doi: 10.1007/s10096-025-05105-9. Epub 2025 Mar 13. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40080302
-
Eradication of Helicobacter pylori: challenges and advances.Iran J Microbiol. 2025 Aug;17(4):593-599. doi: 10.18502/ijm.v17i4.19248. Iran J Microbiol. 2025. PMID: 40785711 Free PMC article.
-
Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Microorganisms. 2025 Feb 26;13(3):519. doi: 10.3390/microorganisms13030519. Microorganisms. 2025. PMID: 40142411 Free PMC article. Review.
-
Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial.Nutr J. 2025 Jul 7;24(1):106. doi: 10.1186/s12937-025-01124-6. Nutr J. 2025. PMID: 40624535 Free PMC article. Clinical Trial.
References
-
- J. K. Y. Hooi, W. Y. Lai, W. K. Ng, et al., “Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta‐Analysis,” Gastroenterology 153, no. 2 (2017): 420–429.
-
- L. Zhou, H. Lu, Z. Song, et al., “2022 Chinese National Clinical Practice Guideline on Helicobacter pylori Eradication Treatment,” Chinese Medical Journal 135, no. 24 (2022): 2899–2910.
-
- M. Leja, I. Grinberga‐Derica, C. Bilgilier, and C. Steininger, “Review: Epidemiology of Helicobacter pylori Infection,” Helicobacter 24, no. Suppl 1 (2019): e12635.
-
- P. Malfertheiner, F. Megraud, C. A. O'Morain, et al., “Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report,” Gut 66, no. 1 (2017): 6–30.
-
- A. Lanas and F. K. L. Chan, “Peptic Ulcer Disease,” Lancet 390, no. 10094 (2017): 613–624.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical